| Back |
|
| In breath taking situation |
| Product Name: |
|
| Roxithromycin 150 mg, Ambroxol 30 mg |
|
| Effectively prevents secondary infection in respiratory tract disorders |
| Produces synergistic effect - "It has been demonstrated that there is a synergism between mucolytics and antibiotics in the treatment of exacerbation of chronic bronchitis." |
| Offers built-in additional property to clear respiratory infections |
| Improves quality of life of patients |
| Highly beneficial in complicated chronic obstructive pulmonary disease, asthma and acute bronchitis |
| Also helpful in case of expectoration or the frequency of infective exacerbations |
|
| Roxythromycin : Immunopotent and anti-inflammatory actions
|
| Ambroxol : Mucolytics activity
|
| " Moreover, they act as scavengers of reactive oxygen species. Ambroxol is able to inhibit mediator release involved in the pathogenesis of allergic inflammation."
|
| " Mucolytics have been shown to have a role in improving lung functions and patients quality of life. Undoubtedly they are useful as an adjunctive therapy of respiratory tract disorders."
|
|
| Also available: REFOXIL-50 (Roxithromycin 50 mg), REFOXIL-150 (Roxithromycin 150 mg)
|
|
Medical Jr.
|
| |
|
 |